Top 7 Combination Cardiac Therapies for Dogs in Canada: 2026 Guide

Vetmedin is widely regarded as the cornerstone positive inotrope/vasodilator for canine congestive heart failure and holds a best-in-class position for combination cardiac regimens because it reliably improves cardiac output and quality of life when paired with diuretics and RAAS inhibitors. Compared with the ACE inhibitors and diuretics on this list, Vetmedin is more frequently the foundational agent in multi‑drug protocols — its clinical impact often justifies a higher unit cost by reducing hospitalization days and enabling lower doses of adjunctive drugs in many dogs.

Cardalis combines benazepril with spironolactone to deliver dual RAAS modulation — ACE inhibition plus aldosterone antagonism — in a single product, positioning it as a market leader for simplifying multi‑drug cardiac protocols and improving owner adherence. The bundled formulation can provide technical advantages by addressing aldosterone breakthrough seen with ACE inhibitors alone and offers financial and compliance benefits by reducing pill burden and potentially lowering total pharmacy costs compared with prescribing the two agents separately.

Fortekor is a leading ACE inhibitor for dogs used to blunt RAAS activation in chronic cardiac disease and is valued in multi‑drug regimens for a favorable pharmacokinetic profile and once‑daily dosing that can improve owner compliance versus some alternatives. Financially and operationally it is often more cost‑effective than brand‑only options because benazepril is widely available as generics and pairs synergistically with Vetmedin and loop diuretics to reduce progressive remodeling and diuretic requirements.

Lasix is the prototypical loop diuretic and remains the market leader for rapid control of congestion and pulmonary edema in canine patients, making it essential to most multi‑drug cardiac regimens. Its technical advantage is rapid onset and predictable fluid removal; economically, generic furosemide is inexpensive and widely available, which lowers short‑term treatment costs though it increases the need for laboratory monitoring and electrolyte management when used alongside ACE inhibitors and spironolactone.

Atenolol (generic) is a widely used beta-1 selective blocker that holds a core role in multi-drug cardiac regimens for dogs by providing reliable heart-rate and arrhythmia control with low cost and broad veterinary availability. Compared with sildenafil and spironolactone in this list, atenolol offers a clear technical advantage for rate control and is typically the most cost-effective component, making it a practical backbone in combination therapies aimed at stabilizing cardiac workload before adding pulmonary vasodilators or aldosterone antagonists.

Sildenafil (generic) is the principal pulmonary vasodilator in canine combination cardiac therapy, providing targeted reduction of pulmonary artery pressure and improving exercise tolerance in dogs with pulmonary hypertension. Although generally more expensive than atenolol and sometimes requiring additional monitoring when co-administered, its technical advantage in directly addressing pulmonary vascular resistance makes it a complementary agent to beta-blockers and spironolactone in multi-drug regimens.